Logo

Medtronic Receives the US FDA’s Approval for its PulseSelect PFA System to Treat Atrial Fibrillation

Share this
Medtronic

Medtronic Receives the US FDA’s Approval for its PulseSelect PFA System to Treat Atrial Fibrillation

Shots:

  • The US FDA-approved PulseSelect Pulsed Field Ablation (PFA) System is designed for the treatment of paroxysmal & persistent atrial fibrillation. The safety, efficacy & efficiency of this system were evaluated in a study named (PULSED AF) that depicted 0.7% safety event & 80% clinical success rates in both indications
  • The PulseSelect PFA system is designed with safety features that provide a rapid PVI through consistent and predictable energy delivery & catheter maneuverability
  • It is a plug-and-play system used with any mapping system, with built-in features like phrenic nerve test pulse & a non-therapeutic low voltage pulse, fixed catheter (9) spacing for contiguous ablation (can also be used for pacing & sensing)

Ref: Medtronic | Image: Medtronic

Related Post:- Medtronic Reports (PULSED AF) Trial Results of PulseSelect PFA System for Atrial Fibrillation

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Kritika Jha

Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions